Fig. 4From: Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in SpainCost-effectiveness acceptability curve. Abbreviations: QALY, quality-adjusted life yearBack to article page